期刊文献+

美罗华单抗的^(90)Y标记的实验研究 被引量:1

^(90)Y radiolabeling of chimeric anti-CD20 monoclonal antibody
下载PDF
导出
摘要 目的:使用新型DOTA类螯合剂p-SCN-BZ-DOTA对进口人鼠嵌合型抗CD20单抗美罗华进行90Y标记,确定最佳标记条件。方法:采用先螯合抗体再标记核素的方法制备放免复合物,在固定抗体、螯合剂、核素用量及缓冲液的前提下,采用正交设计考察标记反应中的3个关键因素pH值、温度、标记时间对其比活度的影响,确定最佳标记条件。结果:不同标记条件下,放免复合物的比活度波动在0.122~0.327 mCi/mg之间,统计分析后发现,最佳标记条件为:pH值7.5,4℃反应2 h。结论:使用新型螯合剂p-SCN-BZ-DOTA可成功制备90Y-抗CD20单抗放射免疫药物,其放化纯度可满足临床研究使用。
出处 《第二军医大学学报》 CAS CSCD 北大核心 2005年第12期1412-1414,共3页 Academic Journal of Second Military Medical University
  • 相关文献

参考文献15

  • 1Wiseman GA,White CA,Sparks RB,et al.Biodistribution and dosimetry results from a phase Ⅲ prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade,follicular,or transformed B-cell non-Hodgkin's lymphoma[J].Oncol Hematol,2001,39(1-2):181-94.
  • 2Shan D,Ledbetter JA,Press OW.Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells[J].Cancer Immunol Immunother,2000,48(12):673-683.
  • 3Wagner HN Jr,Wiseman GA,Marcus CS,et al.Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody[J].J Nucl Med,2002,43(2):267-272.
  • 4Wessels BW,Rogus RD.Radionuclide selection and model absorbed dose calculation for radiolabeled tumor associated antibodies[J].Med Phys,1984,11(5):638-645.
  • 5吴永慧,刘斌,左育红,刘启民.^(90)Y标记单克隆抗体用于放免治疗的研究Ⅰ.四种^(90)Y标记物的24小[J].同位素,1994,7(2):98-102. 被引量:4
  • 6Stimmel JB,Stockstill ME,Kull FC Jr.90Y chelation properties of tetraazatetraacetic acid macrocycles,diethylenetriaminepentaacetic acid analogues,and a novel terpyridine acyclic chelator[J].Bioconjug Chem,1995,6(2):219-225.
  • 7Williams LE,Lewis MR,Bebb GG,et al.Biodistribution of 111In-and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice:comparison of stable and chemically labile linker systems[J].Bioconjug Chem,1998,9(1):87-93.
  • 8Lewis MR,Shively JE.Maleimidocysteineamido-DOTA derivatives:new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-cleavage reactions[J].Bioconjug Chem,1998,9(1):72-86.
  • 9Li M,Meares CF,Zhong GR,et al.Labeling monoclonal antibodies with 90Y-and 111In -DOTA chelates:a simple and efficient method[J].Bioconjug Chem,1994,5(2):101-104.
  • 10Lewis MR,Raubitschek A,Shively JE.A facile,water-soluble method for modification of proteins with DOTA.use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates[J].Bioconjug Chem,1994,5(6):565-576.

共引文献3

同被引文献21

  • 1张锦明,林琼芳.^90Y标记单克隆抗体3H11[J].中华核医学杂志,1993,13(3):173-175. 被引量:3
  • 2吴永慧,刘斌,左育红,刘启民.^(90)Y标记单克隆抗体用于放免治疗的研究Ⅰ.四种^(90)Y标记物的24小[J].同位素,1994,7(2):98-102. 被引量:4
  • 3钟高仁,朱建华,朱桐.单克隆抗体Lym—1的^(90)Y预标记法研究[J].核技术,1996,19(7):440-444. 被引量:1
  • 4仇凯,陈志南.放射性核素标记单克隆抗体进行肿瘤导向诊治的方法和进展[J].第四军医大学学报,1994,15:增刊:75-77.
  • 5Yuanfang L, Chuanchu W. Radiolabeling of Monoclonal Antibodies with Metal Chelates[J]. Pure &Appl Chem, 1991, 63(3): 427-463.
  • 6Shuang Liu, Scott Edwards. Bifunctional Chelators for Therapeutic LanthanideRadiopharmaceuticals[J]. BioconjugateChem, 2001, 12: 7-34.
  • 7Sundberg M W, Meares C F, Goodwin D Aet al. Selective Binding of Metal Ions to Macromolecules using Bifunctional Analogs of EDTA[J]. J Med Chem, 1974, 17: 1304.
  • 8Moi M K, Meares C F, McCall M Jet al. Copper Chelates as Probes of Biological Systems: Stable Copper Complexes with a Macrocyclic BifunctionalChelatingAgent[J]. Anal Biochem, 1985, 148: 249.
  • 9Moi M K, Denardo S J, Meares C F. Stable Bifunctional Chelates of Metals usedin Radiotherapy[J]. Cancer Res(suppl), 1990, 50(3): 789.
  • 10Marvin Bums. New Promise for Therapeutic Radiopharmaceuticals [J]. Bio-TechSystemslnc, 2006, 5, 19.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部